Ireland's Jazz Pharma Q2 revenue beats estimates on Zepzelca higher sales
JAZZ•Outlook
- Jazz raises 2026 revenue guidance to $4.60-$4.75 bln
- Company expects 2026 non-GAAP gross margin of 90%-91% and effective tax rate of 11.5%-13.5%
- Jazz prepared to launch Ziihera in HER2+ 1L GEA after expected FDA approval (PDUFA date August 25, 2026)
Overview
- Ireland biopharma firm's Q2 revenue rose 16% yr/yr, beating analyst expectations
- Adjusted EPS for Q2 missed analyst expectations
- Company raised 2026 revenue guidance after strong first half
Result drivers
- XYWAV patient growth - Co said Xywav sales rose 13% YoY in Q2, driven by 525 net patient adds and continued physician and patient demand for low-sodium formulation
- Epidiolex demand - Epidiolex/Epidyolex sales grew 16% YoY in Q2, attributed to continued strong demand and expanded clinical development
- Zepzelca uptake - Zepzelca sales increased 42% YoY in Q2, supported by continued uptake in first-line maintenance ES-SCLC, partially offset by decline in second-line use
